Author’s response to reviews

Title: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

Authors:

Masatoshi Eto (etom@kumamoto-u.ac.jp)
Yoshiaki Kawano (yoshiaki.kawano@gmail.com)
Yoshihiko Hirao (hiraoyos@gmail.com)
Koji Mita (mita@plum.ocn.ne.jp)
Yoichii Arai (yarai@uro.med.tohoku.ac.jp)
Taiji Tsukamoto (taijit@sapmed.ac.jp)
Katsuyoshi Hashine (khashine@shikoku-cc.go.jp)
Akio Matsubara (matsua@hiroshima-u.ac.jp)
Tomoaki Fujioka (tomof@iwate-med.ac.jp)
Go Kimura (gokimura@nms.ac.jp)
Nobuo Shinohara (nozomis@mbj.nifty.com)
Katsunori Tatsugami (ktatsu@uro.med.kyushu-u.ac.jp)
Shiro Hinotsu (hinotsus@cc.okayama-u.ac.jp)
Seiji Naito (naito@uro.med.kyushu-u.ac.jp)

Version: 5 Date: 19 June 2015

Author’s response to reviews: see over
Ms. Cherry Battad  
Journal Editorial Office  
BioMed Central

RE: MS: 7647898741522697  
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

Dear Ms. Cherry Battad:

Thank you very much for the e-mail of 14 June, 2015, along with additional editorial request. We have read them carefully, and have corrected the manuscript accordingly. The following alterations have been made:

For additional editorial request:
Q1: Trial registration information: please include the date of trial registration at the end of the abstract.
A: According to the additional editorial request, we have added “The date of trial registration: 9\textsuperscript{th} September, 2009” at the end of the ABSTRACT on page 5, line 79.

Q2: Authors' contributions: please confirm whether all authors approved the final version of the manuscript.
A: According to the additional editorial request, we have added a sentence, “All authors read and approved the final version of the manuscript.” at the end of Author’s contributions on page 19, line 339.

We would like to thank you for helping us improve our manuscript. We hope that the revised manuscript is now suitable for publication in BMC Cancer.

Best Wishes,

Masatoshi Eto, MD, PhD  
Department of Urology  
Faculty of Life Sciences  
Kumamoto University  
Kumamoto, Japan